Overdose, Behavioral Health Services, and Medications for Opioid Use Disorder After a Nonfatal Overdose

被引:3
|
作者
Jones, Christopher M. [1 ]
Shoff, Carla [2 ]
Blanco, Carlos [3 ]
Losby, Jan L. [4 ]
Ling, Shari M. [5 ]
Compton, Wilson M. [3 ]
机构
[1] Subst Abuse & Mental Hlth Serv Adm, Ctr Subst Abuse Prevent, 5600 Fishers Ln, Rockville, MD 20857 USA
[2] Ctr Medicare & Medicaid Serv, Off Administrator, Baltimore, MD USA
[3] NIH, Natl Inst Drug Abuse, Bethesda, MD USA
[4] CDCP, Natl Ctr Injury Prevent & Control, Atlanta, GA USA
[5] Ctr Medicare Medicaid Serv, Ctr Clin Stand & Qual, Baltimore, MD USA
基金
美国国家卫生研究院;
关键词
NALOXONE; DEATHS;
D O I
10.1001/jamainternmed.2024.1733
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Importance Recognizing and providing services to individuals at highest risk for drug overdose are paramount to addressing the drug overdose crisis. Objective To examine receipt of medications for opioid use disorder (MOUD), naloxone, and behavioral health services in the 12 months after an index nonfatal drug overdose and the association between receipt of these interventions and fatal drug overdose. Design, Setting, and Participants This cohort study was conducted in the US from January 2020 to December 2021 using claims, demographic, mortality, and other data from the Centers for Medicare & Medicaid Services, the Centers for Disease Control and Prevention, and other sources. The cohort comprised Medicare fee-for-service beneficiaries aged 18 years or older with International Statistical Classification of Diseases, Tenth Revision, Clinical Modification codes for a nonfatal drug overdose. Data analysis was performed from February to November 2023. Exposures Demographic and clinical characteristics, substance use disorder, and psychiatric comorbidities. Main Outcomes and Measures Receipt of MOUD, naloxone, and behavioral health services as well as subsequent nonfatal and fatal drug overdoses. Results The cohort consisted of 136 762 Medicare beneficiaries (80 140 females [58.6%]; mean (SD) age of 68.2 [15.0] years) who experienced an index nonfatal drug overdose in 2020. The majority of individuals had Hispanic (5.8%), non-Hispanic Black (10.9%), and non-Hispanic White (78.8%) race and ethnicity and lived in metropolitan areas (78.9%). In the 12 months after their index nonfatal drug overdose, 23 815 beneficiaries (17.4%) experienced at least 1 subsequent nonfatal drug overdose and 1323 (1.0%) died of a fatal drug overdose. Opioids were involved in 72.2% of fatal drug overdoses. Among the cohort, 5556 (4.1%) received any MOUD and 8530 (6.2%) filled a naloxone prescription in the 12 months after the index nonfatal drug overdose. Filling a naloxone prescription (adjusted odds ratio [AOR], 0.70; 95% CI, 0.56-0.89), each percentage of days receiving methadone (AOR, 0.98; 95% CI, 0.98-0.99) or buprenorphine (AOR, 0.99; 95% CI, 0.98-0.99), and receiving behavioral health assessment or crisis services (AOR, 0.25; 95% CI, 0.22-0.28) were all associated with reduced adjusted odds of fatal drug overdose in the 12 months after the index nonfatal drug overdose. Conclusions and Relevance This cohort study found that, despite their known association with reduced risk of a fatal drug overdose, only a small percentage of Medicare beneficiaries received MOUD or filled a naloxone prescription in the 12 months after a nonfatal drug overdose. Efforts to improve access to behavioral health services; MOUD; and overdose-prevention strategies, such as prescribing naloxone and linking individuals to community-based health care settings for ongoing care, are needed.
引用
收藏
页码:954 / 962
页数:9
相关论文
共 50 条
  • [1] MORTALITY AFTER NONFATAL OPIOID OVERDOSE: MEDICATIONS FOR OPIOID USE DISORDER ARE ASSOCIATED WITH LOWER RISK
    Larochelle, Marc
    Bernson, Dana
    Land, Thomas
    Stopka, Thomas
    Walley, Alexander Y.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2017, 32 : S250 - S250
  • [2] Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Mortality
    Brennan, Lawrence V.
    ANNALS OF INTERNAL MEDICINE, 2019, 170 (06) : 430 - 430
  • [3] OPIOID PRESCRIBING AFTER NONFATAL OVERDOSE AND ASSOCIATION WITH REPEAT OVERDOSE
    Larochelle, Marc
    Liebschutz, Jane M.
    Zhang, Fang
    Ross-Degnan, Dennis
    Wharam, James F.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2015, 30 : S216 - S216
  • [4] Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality A Cohort Study
    Larochelle, Marc R.
    Bernson, Dana
    Land, Thomas
    Stopka, Thomas J.
    Wang, Na
    Xuan, Ziming
    Bagley, Sarah M.
    Liebschutz, Jane M.
    Walley, Alexander Y.
    ANNALS OF INTERNAL MEDICINE, 2018, 169 (03) : 137 - +
  • [5] Opioid Prescribing After Nonfatal Overdose and Association With Repeated Overdose
    Sullivan, Charles T.
    ANNALS OF INTERNAL MEDICINE, 2016, 165 (05) : 376 - 376
  • [6] Opioid overdose survivors: Medications for opioid use disorder and risk of repeat overdose in Medicaid patients
    Crystal, Stephen
    Nowels, Molly
    Samples, Hillary
    Olfson, Mark
    Williams, Arthur Robin
    Treitler, Peter
    DRUG AND ALCOHOL DEPENDENCE, 2022, 232
  • [7] Prior use of medications for opioid use disorder in ED patients with opioid overdose: prevalence, misuse and overdose severity
    Shastry, Siri
    Nobel, Ishak
    Allen, Lisa R.
    Richardson, Lynne D.
    Vidal, Kavey
    Manini, Alex F.
    AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2022, 51 : 114 - 118
  • [8] Causes of Death After Nonfatal Opioid Overdose
    Olfson, Mark
    Crystal, Stephen
    Wall, Melanie
    Wang, Shuai
    Liu, Shang-Min
    Blanco, Carlos
    JAMA PSYCHIATRY, 2018, 75 (08) : 820 - 827
  • [9] Opioid Prescribing After Nonfatal Overdose and Association With Repeated Overdose A Cohort Study
    Larochelle, Marc R.
    Liebschutz, Jane M.
    Zhang, Fang
    Ross-Degnan, Dennis
    Wharam, J. Frank
    ANNALS OF INTERNAL MEDICINE, 2016, 164 (01) : 1 - +
  • [10] Risk of recurrent overdose associated with prescribing patterns of psychotropic medications after nonfatal overdose
    Okumura, Yasuyuki
    Nishi, Daisuke
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2017, 13 : 653 - 665